Join to View Full Profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-3196
Fax+1 614-293-4812
Dr. Bhat is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Seema A. Bhat is an Oncologist in Columbus, OH and is affiliated with multiple hospitals in the area, including James Cancer Hospital and Solove Research Institute and Ohio State University Wexner Medical Center. She received her medical degree from Government Medical College of Jammu and Kashmir and has been in practice for 19 years. She also speaks multiple languages, including Kashmiri, Urdu and Hindi. She specializes in hematologic/Medical oncology and is experienced in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, cold agglutinin disease, Autoimmune hemolytic anemia, Lymphomas and related disorders.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 2008 - 2011- University at BuffaloResidency, Internal Medicine, 2004 - 2008
Government Medical College of Jammu and KashmireClass of 1999
Certifications & Licensure
OH State Medical License 2018 - 2027
NY State Medical License 2011 - 2020
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Sunrise Patient Portal and Sunrise Ambulatory Care EHR, Allscripts, 2013-2014
- CMS Meaningful Use Stage 1 Certification Sunrise Patient Portal and Sunrise Acute Care EHR, Allscripts, 2013-2014
- CMS Meaningful Use Stage 1 Certification Sunrise Acute Care Module Set, Allscripts, 2013-2014
Clinical Trials
- Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia Start of enrollment: 2012 Apr 01
- First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Start of enrollment: 2020 Mar 13
Publications & Presentations
PubMed
- A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.Aseel Alsouqi, Ying Huang, Beth Christian, John Reneau, Seema A Bhat
European Journal of Haematology. 2026-03-01 - PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.Britten K Gordon, Elizabeth M Muhowski, Jyotsana Singh, Janani Ravikrishnan, Arnau Peris-Cuesta
Blood Cancer Discovery. 2026-01-12 - 1 citationsFrontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton's Tyrosine Kinase Inhibitors: A Comprehensive Overview.Seema Ali Bhat, Jennifer A Woyach
Hematology/oncology Clinics of North America. 2025-10-01
Abstracts/Posters
- Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK MutationsSeema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLLSeema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected CytotoxicitySeema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
CLL: Hematologists Face off on Best Long-Term StrategyJuly 9th, 2025- ICML 2025: Progress and Future Directions in CLL TreatmentJuly 7th, 2025
- Novel Therapies and Their Impact on Treatment Pathways for Chronic Lymphocytic LeukemiaJanuary 13th, 2025
Committees
- Chairperson, P&T Comittee Roswell Park Comphrensive Cancer center 2014 - 2017
Professional Memberships
- Member
- Member
- Member
Other Languages
- Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
